Gilead Sciences (NQ:GILD)

144.74 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

78 79 Next >

GILEAD SCIENCES INC (NASDAQ:GILD): A Prime Value Investing Candidate with Strong Fundamentals ↗

September 13, 2025

Gilead Sciences (GILD) is a strong value investing candidate, trading at a significant discount with high profitability, solid financial health, and positive growth prospects.

Via Chartmill

SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks? ↗

September 11, 2025

Via Stocktwits

Tariffs Cast a Long Shadow: Consumer Prices Soar Across Essential Goods

September 10, 2025

American households are bracing for a significant financial hit as a wave of tariff-induced inflation sweeps across critical consumer goods and services. From the family car to essential baby products,...

Via MarketMinute

Why Is Novo Nordisk’s Stock Rising Premarket Today? ↗

September 10, 2025

Via Stocktwits

Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued ↗

September 09, 2025

Via Stocktwits

Cooling Wages Cast a Shadow: Economic Recovery at Risk as Consumer Spending Slows

September 10, 2025

The American economy is facing a new headwind as weakening wage growth begins to temper consumer spending, raising concerns about the pace and sustainability of the broader economic recovery. Recent...

Via MarketMinute

Topics Credit Cards Economy Supply Chain

InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at LSX World Congress 2025

September 10, 2025

Via Investor Brand Network

Topics Intellectual Property

Wolfspeed, Nvidia, Gilead, SLBM, Corning: What Sparked Heavy After-Hours Trading In These 5 Stocks? ↗

September 09, 2025

On Monday, the tech-heavy Nasdaq Composite climbed to a new high despite the ongoing uncertainty regarding the state of the U.S. economy and the rate outlook.

Via Stocktwits

Topics Artificial Intelligence Bankruptcy Economy

Global Economic Slowdown and Escalating Tariffs: A Looming Threat to Market Growth

September 08, 2025

The global economy is currently grappling with a projected deceleration in GDP growth, a situation severely exacerbated by an unprecedented escalation of U.S. tariffs. These twin forces are creating a...

Via MarketMinute

Topics Economy Supply Chain World Trade

2024 R&D Spending and Intensity Benchmarks

September 08, 2025

Via PRLog

Topics Supply Chain

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

September 04, 2025

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV

September 04, 2025

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy

September 03, 2025

From Gilead Sciences, Inc.

Via Business Wire

1 Healthcare Stock to Consider Right Now and 2 We Question

September 03, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID...

Via StockStory

Topics Stocks

Beating The September Curse–These 10 Stocks Shine While The S&P 500 Stumbles ↗

September 02, 2025

September is historically the worst month for stocks, but these 10 S&P 500 companies have consistently delivered gains.

Via Benzinga

Topics Stocks

Veeva Makes A Bearish Move On One Pockmark In Its Quarterly Report ↗

August 27, 2025

The company beat second-quarter expectations, with the exception of one key metric.

Via Investor's Business Daily

Eli Lilly Scores Another Weight-Loss Win; Viking, Novo Stocks Slump ↗

August 26, 2025

Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful test.

Via Investor's Business Daily

Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win ↗

August 26, 2025

The drug is soon to launch in Europe with a new name and a big potential market.

Via Investor's Business Daily

European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention

August 26, 2025

From Gilead Sciences, Inc.

Via Business Wire

Options Corner: Why The Market Could Be Prescribing A Bull Call Spread For Gilead Sciences ↗

August 25, 2025

While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an opportunity.

Via Benzinga

Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗

August 22, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 22, 2025

Via Benzinga

Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy. ↗

August 22, 2025

The tariffs will impact products imported from Europe, the Trump administration said late Thursday.

Via Investor's Business Daily

Topics ETFs Government Intellectual Property

Market Monitor News August 22 BMO - Coty Crumbles, Powell Looms: Wall Street Cautious Amid Mixed Signals ↗

August 22, 2025

Markets dipped Thursday as Coty issued a dismal forecast, Gilead faced headwinds with its new HIV drug, and investors turned cautious ahead of Fed Chair Powell’s Jackson Hole speech. Solid PMI data...

Via Chartmill

Topics Economy

Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy ↗

August 21, 2025

Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.

Via Benzinga

Why Gilead Sciences (GILD) Shares Are Sliding Today

August 21, 2025

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to...

Via StockStory

Topics Earnings

These S&P500 stocks are gapping in today's session ↗

August 21, 2025

Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug ↗

August 21, 2025

Insurance coverage is key for any new drug. But it's looking tenuous for Gilead Sciences' newest HIV prevention drug.

Via Investor's Business Daily

CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans ↗

August 21, 2025

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Via Benzinga

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform

August 21, 2025

From Gilead Sciences, Inc.

Via Business Wire

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

78 79 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.